NCT00822328|CompletedPhase 2Results
Fermented Milk Drink on Human Intestinal Microflora
Effects of a Fermented Milk Drink Containing Lactobacillus Casei Strain Shirota on the Human Intestinal Microflora
Loading search results
Sponsor study identifier
interventional
24
1 country
1
Study Start
January 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2009
Actual (reported)Study Completion
March 2009
Actual (reported)Fermented milk is a popular drink. Recent studies revealed that some fermented milk containing some strains of lactic acid bacteria have health-promoting effects through improvement of the intestinal microflora and modulation of the immune system. Lactobacillus casei strain Shirota (LcS) is a probiotic bacterium used in the production of fermented milk products and lactic acid bacteria preparations. LcS has been shown to modify allergen-induced immune responses in allergic rhinitis, altering fermentation patterns in the small bowel, prevention of recurrent urinary tract infections in women. Yakult®300 is a fermented milk containing at least 3x10\^10 live LcS cells per 100 ml bottle. This study aimed to evaluate the effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the human intestinal microflora.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2009
Date type not reportedThis date has not been verified as actual or estimated.
January 9, 2009
Actual (reported)January 14, 2009
Actual (reported)March 2009
Actual (reported)March 2009
Actual (reported)August 19, 2009
Actual (reported)Modification of the Composition of the Intestinal Microflora: Bifidobacterium
Fecal specimens were obtained from all 24 healthy volunteers at week 0, 1, 2, 3, 4, 5, 6. Bifidobacterium was cultured. Bacterial colonies were counted.
week 0, 1, 2, 3, 4, 5, 6.
Modification of the Composition of the Intestinal Microflora: Clostridium Perfringens
Fecal specimens were obtained from all 24 healthy volunteers at week 0, 1, 2, 3, 4, 5, 6. Clostridium perfringens was cultured.Bacterial colonies were counted.
week 0, 1, 2, 3, 4, 5, 6.
Modification of the Composition of the Intestinal Microflora: Escherichia Coli, Lactobacillus Spp., Lactobacillus Casei Shirota
at week 0, 1, 2, 3, 4, 5, 6
Fermented milk with Lactobacillus casei strain Shirota 100ml per day
Unfermented milk without Lactobacillus casei strain Shirota 100ml per day
Yakult®300 was given 100 ml once per day for four weeks. Fermented or unfermented milk per 100 ml bottle per day for four week.
Lactobacillus casei strain Shirota
Division of Radiotherapy, Cheng Hsin Rehabilitation Medical Center
Taipei, 112, Taiwan
Yi-Hsien Lin, M.D.
Division of Radiotherapy, Cheng Hsin Rehabilitation Medical Center
24 participants (actual enrollment reported by the registry).
First Submitted
January 9, 2009
First Posted
January 14, 2009
Study Start
January 2009
Date type not reportedThis date has not been verified as actual or estimated.
Fiber Tolerability in Children
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 2009
Actual (reported)Study Completion
March 2009
Actual (reported)Last Updated
September 2, 2009
Results First Posted
August 19, 2009
Record last verified: 2009-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: